VRCA Verrica Pharmaceuticals Inc.

9.5
+0.25  (+3%)
Previous Close 9.25
Open 9.51
Price To Book 2.95
Market Cap 244,230,608
Shares 25,708,485
Volume 51,505
Short Ratio
Av. Daily Volume 36,006

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due 2H 2019.
VP-102
Molluscum contagiosum
Phase 2 data due 2Q 2019.
VP-102
Common warts
Phase 2 trial to be initiated 1H 2019.
VP-102
Genital warts

Latest News

  1. What Type Of Shareholder Owns Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA)?
  2. Verrica Pharmaceuticals Announces Participation in the Jefferies 2019 Healthcare Conference
  3. Verrica Pharmaceuticals Reports First Quarter 2019 Financial Results
  4. Verrica Pharmaceuticals Announces Participation in Upcoming Investor Conferences
  5. Verrica Reports Fourth Quarter and Full Year 2018 Financial Results
  6. Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
  7. Verrica Pharmaceuticals Announces Participation in the Cowen and Company 39th Annual Healthcare Conference
  8. Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting
  9. Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy
  10. West Chester pharma firm to seek FDA OK for skin treatment
  11. Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum
  12. Are Insiders Buying Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock?
  13. Market Trends Toward New Normal in PlayAGS, BEST, Inc. Sponsored ADR, Verrica Pharmaceuticals, Telenav, bluebird bio, and CompX International — Emerging Consolidated Expectations, Analyst Ratings
  14. Verrica Pharmaceuticals Reports Third Quarter 2018 Financial Results
  15. Verrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference
  16. PhaseBio goes public in downsized $46M IPO
  17. The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx